For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial.
CONTEXT Sexual dysfunction is a common adverse effect of antidepressants that frequently results in treatment noncompliance . OBJECTIVE To assess the efficacy of sildenafil citrate in men with sexual dysfunction associated with the use of selective and nonselective serotonin reuptake inhibitor ( SRI ) antidepressants . DESIGN , SETTING , AND PATIENTS Prospect i ve , parallel-group , r and omized , double-blind , placebo-controlled trial conducted between November 1 , 2000 , and January 1 , 2001 , at 3 US university medical centers among 90 male out patients ( mean [ SD ] age , 45 [ 8 ] years ) with major depression in remission and sexual dysfunction associated with SRI antidepressant treatment . INTERVENTION Patients were r and omly assigned to take sildenafil ( n = 45 ) or placebo ( n = 45 ) at a flexible dose starting at 50 mg and adjustable to 100 mg before sexual activity for 6 weeks . MAIN OUTCOME MEASURES The primary outcome measure was score on the Clinical Global Impression-Sexual Function ( CGI-SF ) ; secondary measures were scores on the International Index of Erectile Function , Arizona Sexual Experience Scale , Massachusetts General Hospital-Sexual Functioning Question naire , and Hamilton Rating Scale for Depression ( HAM-D ) . RESULTS Among the 90 r and omized patients , 93 % ( 83/89 ) of patients treated per protocol took at least 1 dose of study drug and 85 % ( 76/89 ) completed week 6 end-point assessment s with last observation carried forward analyses . At a CGI-SF score of 2 or lower , 54.5 % ( 24/44 ) of sildenafil compared with 4.4 % ( 2/45 ) of placebo patients were much or very much improved ( P<.001 ) . Erectile function , arousal , ejaculation , orgasm , and overall satisfaction domain measures improved significantly in sildenafil compared with placebo patients . Mean depression scores remained consistent with remission ( HAM-D score < or = 10 ) in both groups for the study duration . CONCLUSION In our study , sildenafil effectively improved erectile function and other aspects of sexual function in men with sexual dysfunction associated with the use of SRI antidepressants . These improvements may allow patients to maintain adherence with effective antidepressant treatment
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .